Energy Fuels Issues Reminder Regarding Expiration of Warrants prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Assets expand immunology portfolio to include B-cell therapy and macrophage modulation - - IND-enabling studies are ongoing and will support the transition of these assets to clinical development in 20222023 - Aurinia Pharmaceuticals Inc. today announced the addition of two novel assets that will expand the Company’s rare autoimmune and kidney-related disease pipeline. “Over the past year, in anticipation of .
Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application for Voclosporin with the European Medicines Agency investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.